Hemostasis and Tissue Sealing Agents Market Size Forecast: Share, Trends & Revenue Outlook 2026-2034

Market Overview:

According to IMARC Group’s latest research publication, “Hemostasis and Tissue Sealing Agents Market Size, Share, Trends and Forecast by Product Type, Material Type, Application, End User, and Region”, the global hemostasis and tissue sealing agents market size was valued at USD 7.68 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 12.61 Billion by 2034, exhibiting a CAGR of 5.65% from 2026-2034, as demand dynamics signal a robust growth trajectory driven by rising surgical volumes worldwide.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How AI is Reshaping the Future of Hemostasis and Tissue Sealing Agents Market

• Robotic and image-guided surgery is raising the bar for hemostatic products. High-definition imaging and robotic systems are expanding minimally invasive procedures across specialties, which creates demand for agents designed for use through small incisions.
• Government investment is bringing advanced surgical capability to emerging markets. Governments across the Middle East and Africa are launching public robotic surgery facilities, while the Brazilian government has directed substantial funding toward public healthcare infrastructure.
• Companies are solving practical operating room problems. Baxter International introduced its Hemopatch sealing hemostat with room-temperature storage in Europe, removing the need for refrigeration and offering a three-year shelf life that reduces product wastage.
• Clinical performance data is driving adoption. Ethicon, part of Johnson and Johnson, received European approval for its ETHIZIA hemostatic sealing patch, which stops bleeding in 30 seconds for 80% of patients.
• Biomaterial innovation is reaching adjacent technologies. GELITA launched its Endotoxin Controlled Excipients range, with applications spanning medical equipment, vaccine stabilization, and 3D bioprinting.

Key Trends in the Hemostasis and Tissue Sealing Agents Market

• Surging Demand for Minimally Invasive Surgeries: Patients benefit from less pain and shorter hospital stays, which has driven acceptance among clinicians and patients alike. In India, Apollo Spectra is performing the Rafaelo procedure, a radiofrequency ablation technique for hemorrhoids developed in Poland that uses local anesthesia.
• Technological Advancements in Product Formulations: Biodegradable and biocompatible agents can be absorbed by the body over six to eight weeks without needing removal. Better delivery systems and enhanced clotting properties are improving efficacy, safety, and ease of use.
• Rising Prevalence of Chronic Diseases: Cardiovascular disease, cancer, and diabetes drive constant demand for surgery. Chronic wounds such as diabetic foot ulcers, pressure sores, and venous ulcers also require surgical debridement and closure where these agents are essential.
• Room-Temperature and Easy-to-Handle Products: Product design is moving toward longer shelf life and simpler storage, as seen with Baxter’s three-year shelf life Hemopatch, which supports surgical efficiency in both open and minimally invasive procedures.
• Growing Role of Sealants Over Sutures: Surgeons increasingly prefer products that deliver faster wound closure, shorter operating times, and lower post-operative infection risk compared with traditional suturing.

Growth Factors in the Hemostasis and Tissue Sealing Agents Market

• Rising Surgical Volumes: According to the International Journal of Surgery, approximately 310 million major surgeries are carried out annually worldwide, with 40 to 50 million taking place in the United States. Cardiovascular, orthopedic, and general surgeries increasingly rely on effective hemostatic control.
• Chronic Disease Burden in the United States: Hypertension cases are expected to rise by 27.2%, reaching 162.5 million from 127.8 million, according to the CRT Group Foundation, pushing demand for surgical care. The American Heart Association and American College of Cardiology have also set a target for healthy blood pressure below 130/80 mm Hg.
• Expanding Geriatric Population: Older adults are more susceptible to chronic ailments and surgical complications, which supports sustained use of hemostats and sealants across hospitals and ambulatory surgical centers.
• Favorable Reimbursement and Regulation: North America benefits from strong reimbursement policies, while Europe’s Medical Device Regulation has strengthened product quality standards and promoted clinically validated agents. The United States minimally invasive surgery market alone is valued at USD 25.7 Billion.
• Healthcare Infrastructure Growth in Emerging Regions: In India, nearly 100 out of every 1 lakh people are diagnosed with cancer, underscoring the vast patient population that requires surgical intervention. Government policies aimed at improving healthcare access are supporting expansion across Asia-Pacific.

Leading Companies Operating in the Global Hemostasis and Tissue Sealing Agents Industry:

• Advanced Medical Solutions Group plc
• Artivion, Inc
• B. Braun SE
• Baxter International Inc.
• Becton, Dickinson and Company
• BioCer Entwicklungs-GmbH
• Ethicon, Inc. (Johnson & Johnson)
• Medtronic
• Pfizer Inc.
• Terumo Aortic

Hemostasis and Tissue Sealing Agents Market Report Segmentation:

Breakup By Product Type:

• Topical Hemostats
• Adhesive and Tissue Sealant

Adhesive and tissue sealant accounts for the majority of shares at 54% on account of faster wound closure, reduced operating times, and lower post-operative infection risks compared with suturing.

Breakup By Material Type:

• Collagen-based
• Oxidized Regenerated Cellulose (ORC) based
• Gelatin-based
• Polysaccharide-based
• Others

Gelatin-based leads the market with a 33% share owing to proven biocompatibility, cost-effectiveness, and its ability to promote both platelet aggregation and wound healing.

Breakup By Application:

• General Surgery
• Minimally Invasive Surgery
• Others

General surgery dominates the market with a 36% share due to the sheer volume of procedures such as hernia repairs, appendectomies, gallbladder removals, and bowel surgeries.

Breakup By End User:

• Hospitals
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Hospitals lead with a 56% share because they handle the highest volume of surgical procedures and have advanced equipment, trained personnel, and integrated services.

Breakup By Region:

• North America (United States, Canada)
• Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position with a 40% share owing to well-established healthcare infrastructure, high adoption of innovative surgical technologies, favorable reimbursement policies, and the presence of major market players. Asia-Pacific is emerging as the fastest-growing regional market.

Recent News and Developments in Hemostasis and Tissue Sealing Agents Market

• April: Baxter International launched the Hemopatch sealing hemostat with room-temperature storage across European markets, eliminating refrigeration requirements and offering a three-year shelf life.
• Recently: GELITA introduced its Endotoxin Controlled Excipients range, including VACCIPRO and MEDELLAPRO, for uses such as vaccine stabilization, medical equipment, and 3D bioprinting.
• Recently: A minimally invasive Rafaelo procedure for hemorrhoids using radiofrequency ablation under local anesthesia was introduced at Apollo Spectra in India.
• November: Ethicon, part of Johnson and Johnson, gained European approval for its ETHIZIA hemostatic sealing patch, which stops bleeding in 30 seconds for 80% of patients.

If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302